Medical management of langerhans cell histiocytosis from diagnosis to treatment

Bibliography

• Gadner H, Heitger A, Grois N, Treatment strategy for disseminated Langerhans cell histiocytosis. DAL HX-83 Study Group. Med Pediatr Oncol 1994;23:72-80
   PubMedGoogle Scholar
• Gadner H, Grois N, Arico M, A randomized trial of treatment for multisystem Langerhans' cell histiocytosis. J Pediatr 2001;138:728-34
   PubMed Web of Science ®Google Scholar
• Gadner H, Grois N, Potschger U, Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification. Blood 2007;111:2556-62
   PubMed Web of Science ®Google Scholar
• Minkov M, Grois N, Heitger A, Treatment of multisystem Langerhans cell histiocytosis. Results of the DAL-HX 83 and DAL-HX 90 studies. DAL-HX Study Group. Klin Padiatr 2000;212:139-44
   PubMed Web of Science ®Google Scholar
• The French Langerhans' Cell Histiocytosis Study Group. A multicentre retrospective survey of Langerhans' cell histiocytosis : 348 cases observed between 1983 and 1993. Arch Dis Child 1996;75:17-24
   PubMed Web of Science ®Google Scholar
• Chikwava K, Jaffe R. Langerin (CD207) staining in normal pediatric tissues, reactive lymph nodes, and childhood histiocytic disorders. Pediatr Dev Pathol 2004;7:607-14
   PubMed Web of Science ®Google Scholar
• Lau SK, Chu PG, Weiss LM. Immunohistochemical expression of Langerin in Langerhans cell histiocytosis and non-Langerhans cell histiocytic disorders. Am J Surg Pathol 2008;32:615-19
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Harris NL, WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th edition. IARC press; Lyon: 2008
   Google Scholar
• Valladeau J, Ravel O, zutter-Dambuyant C, Langerin, a novel C-type lectin specific to Langerhans cells, is an endocytic receptor that induces the formation of Birbeck granules. Immunity 2000;12:71-81
   PubMed Web of Science ®Google Scholar
• Jaffe R. The diagnostic histopathology of Langerhans cell histiocytosis. In: Weitzman S, Egeler M, editors. Histiocytic Disorders of Children and Adults. Cambridge University Press; Cambridge: 2005. p. 14-39
   Google Scholar
• Howarth DM, Mullan BP, Wiseman GA, Bone scintigraphy evaluated in diagnosing and staging Langerhans' cell histiocytosis and related disorders. J Nucl Med 1996;37:1456-60
   PubMed Web of Science ®Google Scholar
• Phillips M, Allen C, Gerson P, McClain K. Comparison of FDG-PET scans to conventional radiography and bone scans in management of Langerhans cell histiocytosis. Pediatr Blood Cancer 2009;52:97-101
   PubMed Web of Science ®Google Scholar
• Goo HW, Yang DH, Ra YS, Whole-body MRI of Langerhans cell histiocytosis: comparison with radiography and bone scintigraphy. Pediatr Radiol 2006;36:1019-31
   PubMed Web of Science ®Google Scholar
• Vassallo R, Ryu JH, Colby TV, Pulmonary Langerhans'-cell histiocytosis. N Engl J Med 2000;342:1969-78
   PubMed Web of Science ®Google Scholar
• Martin-Duverneuil N, Idbaih A, Hoang-Xuan K, MRI features of neurodegenerative Langerhans cell histiocytosis. Eur Radiol 2006;16:2074-82
   PubMed Web of Science ®Google Scholar
• Prayer D, Grois N, Prosch H, MR imaging presentation of intracranial disease associated with Langerhans cell histiocytosis. AJNR Am J Neuroradiol 2004;25:880-91
   PubMed Web of Science ®Google Scholar
• Minkov M, Grois N, Heitger A, Response to initial treatment of multisystem Langerhans cell histiocytosis: an important prognostic indicator. Med Pediatr Oncol 2002;39:581-5
   PubMedGoogle Scholar
• Tazi A, Soler P, Hance AJ. Adult pulmonary Langerhans' cell histiocytosis. Thorax 2000;55:405-16
   PubMed Web of Science ®Google Scholar
• Braier J, Latella A, Balancini B, Outcome in children with pulmonary Langerhans cell Histiocytosis. Pediatr Blood Cancer 2004;43:765-9
   PubMed Web of Science ®Google Scholar
• Ronceray L, Potschger U, Janka G, Pulmonary involvement in pediatric-onset multisystem langerhans cell histiocytosis: effect on course and outcome. J Pediatr Jan 26 2012. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Grois N, Potschger U, Prosch H, Risk factors for diabetes insipidus in langerhans cell histiocytosis. Pediatr Blood Cancer 2006;46:228-33
   PubMed Web of Science ®Google Scholar
• Barthez MA, Araujo E, Donadieu J. Langerhans cell histiocytosis and the central nervous system in childhood: evolution and prognostic factors. Results of a collaborative study. J Child Neurol 2000;15:150-6
   PubMed Web of Science ®Google Scholar
• Grois N, Fahrner B, Arceci RJ, Central nervous system disease in Langerhans cell histiocytosis. J Pediatr 2010;156:873-81. 881
   PubMed Web of Science ®Google Scholar
• Donadieu J, Rolon MA, Thomas C, Endocrine involvement in pediatric-onset Langerhans' cell histiocytosis: a population-based study. J Pediatr 2004;144:344-50
   PubMed Web of Science ®Google Scholar
• Haupt R, Nanduri V, Calevo MG, Permanent consequences in Langerhans cell histiocytosis patients: a pilot study from the Histiocyte Society-Late Effects Study Group. Pediatr Blood Cancer 2004;42:438-44
   PubMed Web of Science ®Google Scholar
• Bernstrand C, Sandstedt B, Ahstrom L, Henter JI. Long-term follow-up of Langerhans cell histiocytosis: 39 years' experience at a single centre. Acta Paediatr 2005;94:1073-84
   PubMed Web of Science ®Google Scholar
• Sartoris DJ, Parker BR. Histiocytosis X: rate and pattern of resolution of osseous lesions. Radiology 1984;152:679-84
   PubMed Web of Science ®Google Scholar
• Womer RB, Raney RB Jr, D'Angio GJ. Healing rates of treated and untreated bone lesions in histiocytosis X. Pediatrics 1985;76:286-8
   PubMed Web of Science ®Google Scholar
• Donadieu J, Piguet C, Bernard F, A new clinical score for disease activity in Langerhans cell histiocytosis. Pediatr Blood Cancer 2004;43:770-6
   PubMed Web of Science ®Google Scholar
• Canuet M, Kessler R, Jeung MY, Correlation between high-resolution computed tomography findings and lung function in pulmonary Langerhans cell histiocytosis. Respiration 2007;74:640-6
   PubMed Web of Science ®Google Scholar
• Tazi A, Marc K, Dominique S, Serial CT and lung function testing in pulmonary Langerhans cell histiocytosis. Eur Respir J 2012; In press
   Google Scholar
• Nanduri VR, Pritchard J, Levitt G, Glaser AW. Long term morbidity and health related quality of life after multi-system Langerhans cell histiocytosis. Eur J Cancer 2006;42:2563-9
   PubMed Web of Science ®Google Scholar
• Trouillas P, Takayanagi T, Hallett M, International Cooperative Ataxia Rating Scale for pharmacological assessment of the cerebellar syndrome. The Ataxia Neuropharmacology Committee of the World Federation of Neurology. J Neurol Sci 1997;145:205-11
   PubMed Web of Science ®Google Scholar
• Allen CE, Flores R, Rauch R, Neurodegenerative central nervous system Langerhans cell histiocytosis and coincident hydrocephalus treated with vincristine/cytosine arabinoside. Pediatr Blood Cancer 2009;54:416-23
   Web of Science ®Google Scholar
• Idbaih A, Donadieu J, Barthez MA, Retinoic acid therapy in "degenerative-like" neuro-langerhans cell histiocytosis: a prospective pilot study. Pediatr Blood Cancer 2004;43:55-8
   PubMed Web of Science ®Google Scholar
• Imashuku S, Shioda Y, Kobayashi R, Neurodegenerative central nervous system disease as late sequelae of Langerhans cell histiocytosis. Report from the Japan LCH Study Group. Haematologica 2008;93:615-18
   PubMed Web of Science ®Google Scholar
• Egeler RM, Thompson RC Jr, Voute PA, Nesbit ME Jr. Intralesional infiltration of corticosteroids in localized Langerhans' cell histiocytosis. J Pediatr Orthop 1992;12:811-14
   PubMed Web of Science ®Google Scholar
• Sheehan MP, Atherton DJ, Broadbent V, Pritchard J. Topical nitrogen mustard: an effective treatment for cutaneous Langerhans cell histiocytosis. J Pediatr 1991;119:317-21
   PubMed Web of Science ®Google Scholar
• Hadfield PJ, Birchall MA, Albert DM. Otitis externa in Langerhans' cell histiocytosis–the successful use of topical nitrogen mustard. Int J Pediatr Otorhinolaryngol 1994;30:143-9
   PubMed Web of Science ®Google Scholar
• Roger G, Dupre M, Leboulanger N, Cholesteatoma secondary to temporal bone involvement by Langerhans cell histiocytosis: a complication amenable to curative surgery. Otol Neurotol 2009;30:190-3
   PubMed Web of Science ®Google Scholar
• Morimoto A, Ikushima S, Kinugawa N, Improved outcome in the treatment of pediatric multifocal Langerhans cell histiocytosis: results from the Japan Langerhans Cell Histiocytosis Study Group-96 protocol study. Cancer 2006;107:613-19
   PubMed Web of Science ®Google Scholar
• Arico M, Girschikofsky M, Genereau T, Langerhans cell histiocytosis in adults. Report from the International Registry of the Histiocyte Society. Eur J Cancer 2003;39:2341-8
   PubMed Web of Science ®Google Scholar
• Weitzman S, Braier J, Donadieu J, 2'-Chlorodeoxyadenosine (2-CdA) as salvage therapy for Langerhans cell histiocytosis (LCH). results of the LCH-S-98 protocol of the Histiocyte Society. Pediatr Blood Cancer 2009;53:1271-6
   PubMed Web of Science ®Google Scholar
• Bernard F, Thomas C, Bertrand Y, Multi-centre pilot study of 2-chlorodeoxyadenosine and cytosine arabinoside combined chemotherapy in refractory Langerhans cell histiocytosis with haematological dysfunction. Eur J Cancer 2005;41:2682-9
   PubMed Web of Science ®Google Scholar
• Steiner M, Matthes-Martin S, Attarbaschi A, Improved outcome of treatment-resistant high-risk Langerhans cell histiocytosis after allogeneic stem cell transplantation with reduced-intensity conditioning. Bone Marrow Transplant 2005;36:215-25
   PubMed Web of Science ®Google Scholar
• Munn SE, Olliver L, Broadbent V, Pritchard J. Use of indomethacin in Langerhans cell histiocytosis. Med Pediatr Oncol 1999;32:247-9
   PubMedGoogle Scholar
• Ng Wing TS, Martin-Duverneuil N, Idbaih A, Efficacy of vinblastine in central nervous system Langerhans cell histiocytosis: a nation wide retrospective study. Orphanet J Rare Dis 2011;6:83
   PubMed Web of Science ®Google Scholar
• Gavhed D, Laurencikas E, Akefeldt SO, Henter JI. Fifteen years of treatment with intravenous immunoglobulin in central nervous system Langerhans cell histiocytosis. Acta Paediatr 2011;100:e36-9
   PubMed Web of Science ®Google Scholar
• Chohan G, Barnett Y, Gibson J, Langerhans cell histiocytosis with refractory central nervous system involvement responsive to infliximab. J Neurol Neurosurg Psychiatry 2012;83:573-5
   PubMed Web of Science ®Google Scholar
• Broadbent V, Pritchard J. Diabetes insipidus associated with Langerhans cell histiocytosis: is it reversible? Med Pediatr Oncol 1997;28:289-93
   PubMedGoogle Scholar
• Ottaviano F, Finlay JL. Diabetes insipidus and Langerhans cell histiocytosis: a case report of reversibility with 2-chlorodeoxyadenosine. J Pediatr Hematol Oncol 2003;25:575-7
   PubMed Web of Science ®Google Scholar
• Donadieu J, Rolon MA, Pion I, Incidence of growth hormone deficiency in pediatric-onset Langerhans cell histiocytosis: efficacy and safety of growth hormone treatment. J Clin Endocrinol Metab 2004;89:604-9
   PubMed Web of Science ®Google Scholar
• Minkov M, Steiner M, Potschger U, Reactivations in multisystem Langerhans cell histiocytosis: data of the international LCH registry. J Pediatr 2008;153:700-5. 705
   PubMed Web of Science ®Google Scholar
• Badalian-Very G, Vergilio JA, Degar BA, Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood 2010;116:1919-23
   PubMed Web of Science ®Google Scholar
• Davies H, Bignell GR, Cox C, Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54
   PubMed Web of Science ®Google Scholar
• Begum S, Rosenbaum E, Henrique R, BRAF mutations in anaplastic thyroid carcinoma: implications for tumor origin, diagnosis and treatment. Mod Pathol 2004;17:1359-63
   PubMed Web of Science ®Google Scholar
• Ball DW. Selectively targeting mutant BRAF in thyroid cancer. J Clin Endocrinol Metab 2010;95:60-1
   PubMed Web of Science ®Google Scholar
• Poynter JN, Elder JT, Fullen DR, BRAF and NRAS mutations in melanoma and melanocytic nevi. Melanoma Res 2006;16:267-73
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Puzanov I, Kim KB, Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363:809-19
   PubMed Web of Science ®Google Scholar
• Available from: www eurohistio net 2012
   Google Scholar
• Available from: www histiocytesociety org 2012
   Google Scholar
• Talanin NY, Smith SS, Shelley ED, Moores WB. Cutaneous histiocytosis with Langerhans cell features induced by scabies: a case report. Pediatr Dermatol 1994;11:327-30
   PubMed Web of Science ®Google Scholar
• Geissmann F, Nosjean MC, Dezutter C, Accumulation of immature Langerhans cells in human lymph nodes draining chronically inflamed skin. J Exp Med 2002;196:417-30
   PubMed Web of Science ®Google Scholar
• Perret-Court A, Coulibaly B, Ranque S, Intradural dirofilariasis mimicking a Langerhans cell histiocytosis tumor. Pediatr Blood Cancer 2009;53:485-7
   PubMed Web of Science ®Google Scholar
• Maghnie M, Cosi G, Genovese E, Central diabetes insipidus in children and young adults. N Engl J Med 2000;343:998-1007
   PubMed Web of Science ®Google Scholar
• Marchand I, Barkaoui MA, Garel C, Central diabetes insipidus as the inaugural manifestation of Langerhans cell histiocytosis: natural history and medical evaluation of 26 children and adolescents. J Clin Endocrinol Metab 2011;96:E1352-60
   PubMed Web of Science ®Google Scholar
• Favara BE, Jaffe R, Egeler RM. Macrophage activation and hemophagocytic syndrome in langerhans cell histiocytosis: report of 30 cases. Pediatr Dev Pathol 2002;5:130-40
   PubMed Web of Science ®Google Scholar